Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 87 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Sacituzumab govitecan for previously treated advanced non-small cell lung cancer	Sacituzumab Govitecan (IMMU-132; Trodelvy)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Selpercatinib for metastatic RET fusion-positive non-small cell lung cancer	Selpercatinib (LOXO-292; LY3527723)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2019	View \| Download
Selpercatinib for previously untreated advanced RET fusion-positive non-small cell lung cancer	Selpercatinib (LOXO-292; LY3527723)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Selpercatinib for treating advanced solid tumours with RET gene fusion in people aged 12 years and older	Selpercatinib (LOXO-292; LY3527723)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Sintilimab in combination with pemetrexed and platinum chemotherapy for advanced or metastatic non-small cell lung cancer	Carboplatin (Paraplatin) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium) , Sintilimab (IBI 308; IBI 380; Tyvyt)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Subcutaneous atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer	Atezolizumab (Tecentriq; MPDL3280A)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Telisotuzumab vedotin for previously treated c-MET overexpressing EGFR wild-type non-squamous non-small cell lung cancer	Telisotuzumab vedotin (ABBV-399;ABBV 399;ABBV399;ABT-399;Teliso-V)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Tepotinib for advanced non-small cell lung cancer harbouring MET exon14- skipping mutations	Tepotinib (MSC-2156119J; TEPMETKO)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Tiragolumab with atezolizumab and pemetrexed and carboplatin or cisplatin for previously untreated advanced non-small-cell lung cancer	Atezolizumab (Tecentriq; MPDL3280A) , Tiragolumab (RG-6058; MTIG7192A)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Tiragolumab with atezolizumab for previously untreated non-small cell lung cancer	Atezolizumab (Tecentriq; MPDL3280A) , Tiragolumab (RG-6058; MTIG7192A)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download